MERTK mutation update in inherited retinal diseases |
| |
Authors: | Isabelle Audo Saddek Mohand‐Said Elise Boulanger‐Scemama Xavier Zanlonghi Christel Condroyer Vanessa Démontant Fiona Boyard Aline Antonio Cécile Méjécase Said El Shamieh José‐Alain Sahel Christina Zeitz |
| |
Affiliation: | 1. Sorbonne Université, INSERM, CNRS, Institut de la Vision, Paris, France;2. CHNO des Quinze‐Vingts, DHU Sight Restore, Paris, France;3. University College London Institute of Ophthalmology, London, UK;4. Fondation Ophtalmologique Adolphe de Rothschild, Paris, France;5. Clinique Pluridisciplinaire Jules Verne, Nantes, France;6. Department of Medical Laboratory Technology, Faculty of Health Sciences, Beirut Arab University, Beirut, Lebanon;7. Académie des Sciences‐Institut de France, Paris, France;8. Department of Ophthalmology, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania |
| |
Abstract: | MER tyrosine kinase (MERTK) encodes a surface receptor localized at the apical membrane of the retinal pigment epithelium. It plays a critical role in photoreceptor outer segment internalization prior to phagocytosis. Mutations in MERTK have been associated with severe autosomal recessive retinal dystrophies in the RCS rat and in humans. We present here a comprehensive review of all reported MERTK disease causing variants with the associated phenotype. In addition, we provide further data and insights of a large cohort of 1,195 inherited retinal dystrophies (IRD) index cases applying state‐of‐the‐art genotyping techniques and summarize current knowledge. A total of 79 variants have now been identified underlying rod‐cone dystrophy and cone‐rod dystrophy including 11 novel variants reported here. The mutation spectrum in MERTK includes 33 missense, 12 nonsense, 12 splice defects, 12 small deletions, 2 small insertion–deletions, 3 small duplications, and 2 exonic and 3 gross deletions. Altogether, mutations in MERTK account for ~2% of IRD cases with a severe retinal phenotype. These data are important for current and future therapeutic trials including gene replacement therapy or cell‐based therapy. |
| |
Keywords: | inherited retinal dystrophy MERTK mutation spectrum mutation prevalence |
|
|